Conditions: HIV Infections
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 571
Healthy volunteers: no

Brief summary:
The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus (HIV). There is a comparison arm with lopinavir (LPV)/RTV and TDF and a nucleoside.

Detailed description:

Arms:
arm 1: ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice

ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study arm 2: ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice

ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study arm 3: LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice

LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study

Interventions: intervention 1: Atazanavir + ritonavir + tenofovir + nucleoside intervention 2: Atazanavir + saquinavir + tenofovir + nucleoside intervention 3: Lopinavir/ritonavir + tenofovir + nucleoside
Intervention descriptions: intervention 1: Active Comparator, Capsules, tablets, Oral intervention 2: Active Comparator, Capsules, tablets, Oral intervention 3: Active Comparator, Capsules, tablets, Oral

Protocol document: